These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8592480)

  • 1. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment.
    Coen G; Manni M; Addari O; Ballanti P; Pasquali M; Chicca S; Mazzaferro S; Napoletano I; Sardella D; Bonucci E
    Miner Electrolyte Metab; 1995; 21(6):375-82. PubMed ID: 8592480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study.
    Coen G; Mazzaferro S; Ballanti P; Sardella D; Chicca S; Manni M; Bonucci E; Taggi F
    Nephrol Dial Transplant; 1996 May; 11(5):813-9. PubMed ID: 8671900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients.
    Ismail N
    Semin Nephrol; 1997 Jul; 17(4):270-84. PubMed ID: 9241713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone histomorphometry: observations in cases of renal osteodystrophy].
    Spoliti A; Mastrangelo D
    Boll Soc Ital Biol Sper; 1984 Apr; 60(4):693-9. PubMed ID: 6547345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of metabolic acidosis in the pathogenesis of renal osteodystrophy.
    Kraut JA
    Adv Ren Replace Ther; 1995 Jan; 2(1):40-51. PubMed ID: 7614335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of strontium on bone of chronic renal failure rats.
    Schrooten I; Behets GJ; Cabrera WE; Vercauteren SR; Lamberts LV; Verberckmoes SC; Bervoets AJ; Dams G; Goodman WG; De Broe ME; D'Haese PC
    Kidney Int; 2003 Mar; 63(3):927-35. PubMed ID: 12631073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hydroxylated metabolites of vitamin D. Therapeutic use of calcitriol and dihydrotachysterol].
    Stĕpán J; Lachmanová J; Wilczek H; Straková M; Zichová M; Horn V; Tomásek R; Pacovský V
    Cas Lek Cesk; 1985 Dec; 124(50):1550-6. PubMed ID: 3841297
    [No Abstract]   [Full Text] [Related]  

  • 10. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy.
    Ott SM; Maloney NA; Coburn JW; Alfrey AC; Sherrard DJ
    N Engl J Med; 1982 Sep; 307(12):709-13. PubMed ID: 6896740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
    Mora Palma FJ; Ellis HA; Cook DB; Dewar JH; Ward MK; Wilkinson R; Kerr DN
    Q J Med; 1983; 52(207):332-48. PubMed ID: 6647748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of uremia on growth in children.
    Hanna JD; Krieg RJ; Scheinman JI; Chan JC
    Semin Nephrol; 1996 May; 16(3):230-41. PubMed ID: 8734466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low bone turnover in patients with renal failure.
    Couttenye MM; D'Haese PC; Verschoren WJ; Behets GJ; Schrooten I; De Broe ME
    Kidney Int Suppl; 1999 Dec; 73():S70-6. PubMed ID: 10633468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic acidosis and bone disease.
    Eiam-ong S; Kurtzman NA
    Miner Electrolyte Metab; 1994; 20(1-2):72-80. PubMed ID: 8202056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism.
    Baskin E; Ozen S; Karçaaltincaba M; Besbas N; Saatci U; Düzova A; Agras PI; Haliloglu M; Bakkaloglu A
    Int Urol Nephrol; 2004; 36(1):113-8. PubMed ID: 15338687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1,25(OH)2D3 administration on bone in patients with renal failure.
    Malluche HH; Faugere MC
    Kidney Int Suppl; 1990 Sep; 29():S48-53. PubMed ID: 2214547
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease.
    Jara A; Felsenfeld AJ; Bover J; Kleeman CR
    Kidney Int; 2000 Sep; 58(3):1023-32. PubMed ID: 10972667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathological analysis of renal osteodystrophy in 194 cases].
    Yu YF
    Zhonghua Bing Li Xue Za Zhi; 1991 Dec; 20(4):280-3. PubMed ID: 1813163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.